etoposide has been researched along with palbociclib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chmielewska, K; Kluska, M; Pietrzak, J; Robaszkiewicz, A; Rygielska, Ż; Tempka, D; Tokarz, P; Virág, L | 1 |
| Deneen, B; Kfoury, N; McDonald, P; Mohila, CA; Qi, Z; Rockwell, N; Roy, A; Rubin, JB; Sun, T; Tinkum, KL; Warrington, NM; Weir, SJ; Yu, K | 1 |
2 other study(ies) available for etoposide and palbociclib
| Article | Year |
|---|---|
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Daunorubicin; DNA Damage; DNA Glycosylases; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Lung Neoplasms; Piperazines; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Purines; Pyridines | 2018 |
Cooperative p16 and p21 action protects female astrocytes from transformation.
Topics: Animals; Astrocytes; Cell Cycle; Cell Survival; Cell Transformation, Neoplastic; Culture Media, Serum-Free; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Embryo, Mammalian; Etoposide; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Glioblastoma; Karyotyping; Male; Mice; Neurofibromin 1; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Retinoblastoma Protein; RNA, Messenger; Serum; Sex Characteristics; Transfection; Tumor Cells, Cultured | 2018 |